Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2017 Filed Mar 21, 2017 20:45 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 1,472 | $14.95 | $22,006.40 |
DisclosureSEC source: 0001192482-17-000088 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,083 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 20:44 UTC |
Brannelly PaulExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 388 | $14.95 | $5,800.60 |
DisclosureSEC source: 0001192482-17-000087 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,227 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:54 UTC |
Duke Barry SSee remarks
|
GrantStock Option (Right to Purchase) · Derivative | 27,500 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001192482-17-000040 · edgar.xml · derivative · entry 3 Duke Barry S · CIK 0001640699 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:54 UTC |
Duke Barry SSee remarks
|
GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000040 · edgar.xml · nonDerivative · entry 2 Duke Barry S · CIK 0001640699 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,475 F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:56 UTC |
Fleming Alison BChief Technology Officer
|
GrantStock Option (Right to Purchase) · Derivative | 32,500 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001192482-17-000042 · edgar.xml · derivative · entry 3 Fleming Alison B · CIK 0001640701 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2027-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 17:56 UTC |
Fleming Alison BChief Technology Officer
|
GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000042 · edgar.xml · nonDerivative · entry 2 Fleming Alison B · CIK 0001640701 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,701 F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:54 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
GrantStock Option (Right to Purchase) · Derivative | 110,000 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001192482-17-000041 · edgar.xml · derivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:54 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000041 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,555 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:53 UTC |
Brannelly PaulExecutive Vice President & CFO
|
GrantStock Option (Right to Purchase) · Derivative | 32,500 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · derivative · entry 3 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2027-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:53 UTC |
Brannelly PaulExecutive Vice President & CFO
|
GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,615 F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 21:26 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
Exercise / conversionStock Option (Right to Purchase) · Derivative | 3,013 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001192482-17-000027 · edgar.xml · derivative · entry 3 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,013 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the 3,013 option shares are exercisable. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 21:26 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 3,013 | $0.48 | $1,446.24 |
DisclosureSEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 2 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Feb 2, 2017 21:26 UTC |
Heffernan Michael ThomasDirector · Chairman, President and CEO
|
GrantCommon Stock | 1,239 | $10.08 | $12,489.12 |
DisclosureSEC source: 0001192482-17-000027 · edgar.xml · nonDerivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,542 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 27, 2017 Filed Feb 14, 2017 17:54 UTC |
Duke Barry SSee remarks
|
GrantCommon Stock | 834 | $10.08 | $8,406.72 |
DisclosureSEC source: 0001192482-17-000040 · edgar.xml · nonDerivative · entry 1 Duke Barry S · CIK 0001640699 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 27, 2017 Filed Feb 14, 2017 17:56 UTC |
Fleming Alison BChief Technology Officer
|
GrantCommon Stock | 1,240 | $10.08 | $12,499.20 |
DisclosureSEC source: 0001192482-17-000042 · edgar.xml · nonDerivative · entry 1 Fleming Alison B · CIK 0001640701 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,451 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 27, 2017 Filed Feb 14, 2017 22:53 UTC |
Brannelly PaulExecutive Vice President & CFO
|
GrantCommon Stock | 1,006 | $10.08 | $10,140.48 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,365 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.